c-Met

By Targets:	c-Met/HGFR (90) ADC Antibody (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (4) Angiotensin Receptor (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (22) Autophagy (6) Bacterial (1) c-Kit (7) CDK (1) Cytochrome P450 (1) Discoidin Domain Receptor (2) Drug-Linker Conjugates for ADC (2) EGFR (6) FGFR (1) FLT3 (7) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) P-glycoprotein (1) p38 MAPK (1) PARP (1) PDGFR (3) Polo-like Kinase (PLK) (1) PROTACs (3) RAD51 (2) Raf (2) RET (3) RIP kinase (1) ROS Kinase (6) TAM Receptor (8) Trk Receptor (1) VEGFR (14)
By Research Areas:	Cancer (98) Infection (1) Inflammation/Immunology (2) Metabolic Disease (3) Neurological Disease (3)
Click Chemistry:	Alkynes (2)

Targets Recommended: c-Met/HGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15735

c-Met inhibitor 1	c-Met/HGFR	Cancer
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

HY-149880

c-Met-IN-18	c-Met/HGFR	Cancer
c-Met-IN-18 is ATP competitive type-III c-MET inhibitor of WT and D1228V mutant c-MET. c-Met-IN-18 has inhibitory for WT/D1228V with an IC₅₀ value of 0.013/0.20 ^e.c-Met-IN-18 can be used for the research of c-MET driven cancers . c-Met-IN-18 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115937

c-Met-IN-9	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC₅₀ of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities .

HY-150582

c-Met-IN-14	c-Met/HGFR c-Kit FLT3 Apoptosis	Cancer
c-Met-IN-14 (compound 26af) is a selective inhibitor of *c-Met* kinase from N-sulfonylamidine-based derivatives, with an IC₅₀ value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner .

HY-157302

c-Met-IN-21

c-Met/HGFR Cancer

c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .
HY-147694

c-Met-IN-11

c-Met/HGFR VEGFR Cancer

c-Met-IN-11 (compound 3) is a potent c-MET and VEGFR-2 inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively .

c-Met-IN-21	c-Met/HGFR	Cancer
c-Met-IN-21 (compound 54) is a *c-met* inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

c-Met-IN-11	c-Met/HGFR VEGFR	Cancer
c-Met-IN-11 (compound 3) is a potent *c-MET* and VEGFR-2 inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively .

HY-157387

c-Met-IN-22	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-22 (compound 51am) is an orally active inhibitor against *c-Met* with an IC₅₀ value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis .

HY-153831

c-Met-IN-17	c-Met/HGFR	Cancer
c-Met-IN-17 is a potent *c-Met* kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148279

c-Met-IN-15

c-Met/HGFR Cancer

c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

c-Met-IN-15	c-Met/HGFR	Cancer
c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II *c-Met* kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-161353

c-Met-IN-23	c-Met/HGFR P-glycoprotein	Cancer
c-Met-IN-23 (Compound 12g) is a *c-Met* inhibitor (IC₅₀ = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent .

HY-120908

c-Met-IN-16

c-Met/HGFR Cancer

c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .
HY-101773

c-Met-IN-2

c-Met/HGFR Cancer

c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC₅₀ of 0.6 nM, with antitumor activity.

c-Met-IN-16	c-Met/HGFR	Cancer
c-Met-IN-16 is a *c-Met* inhibitor that can be used for cancer research .

c-Met-IN-2	c-Met/HGFR	Cancer
c-Met-IN-2 is a potent, selective and orally available *c-Met* inhibitor, with an IC₅₀ of 0.6 nM, with antitumor activity.

HY-150004

c-Met/HDAC-IN-3	c-Met/HGFR HDAC Apoptosis	Cancer
c-Met/HDAC-IN-3 (Compound 15f) is a dual *c-Met* and HDAC inhibitor with IC₅₀ values of 12.50 nM and 26.97 nM against c-Met and HDAC1, respectively. c-Met/HDAC-IN-3 induces apoptosis and cause cell cycle arrest in G2/M phase .

HY-101031

c-Met-IN-1

c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC₅₀ of 1.1 nM, with antitumor activity. .

c-Met-IN-1
c-met-IN-1 (compound 16) is a potent and selective *c-Met* inhibitor, with IC₅₀ of 1.1 nM, with antitumor activity. .

HY-150576

c-Met-IN-13	c-Met/HGFR	Cancer
c-Met-IN-13 is a potent *c-Met* inhibitor with an IC₅₀ value of 2.43 nM. c-Met-IN-13 shows excellent cytotoxicity for cancer cells. c-Met-IN-13 shows antiproliferative activity in a concentration- and time- dependent manner. c-Met-IN-13 has the potential for the research of cancer .

HY-143462

c-Met/HDAC-IN-2	HDAC c-Met/HGFR Apoptosis	Cancer
c-Met/HDAC-IN-2 is a highly potent *c-Met* and HDAC dual inhibitor with IC₅₀s of 18.49 nM and 5.40 nM for HDAC1 and *c-Met, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines. c-Met/HDAC-IN-2 can cause G2/M-phase arrest and induce apoptosis* in HCT-116. c-Met/HDAC-IN-2 can be used for researching anti-cancer resistance .

HY-156098

c-Met-IN-19	c-Met/HGFR	Cancer
c-Met-IN-19 (Compound 21j) is a *c-Met* inhibitor (IC₅₀: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC₅₀s of 0.25, 0.36, 0.98, 0.76 μM .

HY-146274

c-Met-IN-10	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC₅₀ value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC₅₀s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer .

HY-18711A

SCR-1481B1 Metatinib anhydrous; c-Met inhibitor 2	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 (Metatinib anhydrous) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

HY-145865

c-Met/MEK1/Flt-3-IN-1	Apoptosis	Cancer
Antiproliferative against-3 (comp 33) shows a prominent activity against Hela (IC₅₀ = 0.21 µM), A549 (IC₅₀ = 0.39 µM), and MCF-7 (IC₅₀ = 0.33 µM), respectively. Antiproliferative against-3 (comp 33) also dose dependently induces apoptosis by arresting A549 cells at G1 phase .

HY-163006

*EGFR/c-Met-IN-1*	EGFR c-Met/HGFR	Cancer
EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of *EGFR/c-Met. The IC₅₀ for inhibiting EGFR ^L858R and c-Met* is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo .

HY-161141

*EGFR/c-Met-IN-2*	c-Met/HGFR	Cancer
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of *EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met*-IN-2 has antitumor activity .

HY-149674

VEGFR-2/c-Met-IN-1

VEGFR Cancer

VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and c-Met with IC₅₀s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity .

*VEGFR-2/c-Met-IN-1*	VEGFR	Cancer
VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and *c-Met* with *IC₅₀s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity .*

HY-149675

*VEGFR-2/c-Met-IN-2*	VEGFR c-Met/HGFR	Cancer
VEGFR-2/c-Met-IN-2 (compound 3e) is a *VEGFR-2/c-Met* inhibitor, with IC₅₀ values of 83 and 48 nM, respectively. VEGFR-2/c-Met-IN-2 exhibits cytotoxic activity against HCT-116 cell line (IC₅₀: 3.403 µM) .

HY-161372

*PARP1/c-Met-IN-1*	PARP c-Met/HGFR Apoptosis	Cancer
PARP1/c-Met-IN-1 (Compound 16) is a selective dual inhibitor for PARP1 and *c-Met, with IC₅₀s of 3.3 and 32.2 nM, respectively. PARP1/c-Met-IN-1 induces cell apoptosis* and cell cycle arrest in G2/M phase in MDA-MB-231 cells. PARP1/c-Met-IN-1 exhibits antitumor activity in mice .

HY-50683

JNJ-38877605 3 Publications Verification	c-Met/HGFR	Metabolic Disease Cancer
JNJ-38877605 is an orally active ATP-competitive inhibitor of *c-Met* with an IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .

HY-133083

BAY-474

c-Met/HGFR Cancer

BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 acts as an epigenetics probe .

BAY-474	c-Met/HGFR	Cancer
BAY-474 is a tyrosine-protein kinase *c-Met* inhibitor. BAY-474 acts as an epigenetics probe .

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective *c-Met* kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

HY-147040

ABN401	c-Met/HGFR	Cancer
ABN401 is a highly potent and selective ATP-competitive *c-MET* inhibitor with an IC₅₀ value of 10 nM. ABN401 has cytotoxic activity against MET-addicted cancer cells. ABN401 can inhibit c-MET phosphorylation in tumor tissues. ABN401 can be used for researching anticancer .

HY-15959

Savolitinib 5 Publications Verification Volitinib; HMPL-504; AZD-6094	c-Met/HGFR	Cancer
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable *c-Met* inhibitor with IC₅₀s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity .

HY-18307

SYN1143	c-Met/HGFR	Cancer
SYN1143 is a potent, selective and orally active dual inhibitor of *c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK* with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated .

HY-123961

SJF-8240	PROTACs c-Met/HGFR	Cancer
SJF-8240 (PROTAC 7) is a proteolysis targeting chimera (PROTAC) degrader. SJF-8240 induces polyubiquitination of *c-Met* and inhibits the proliferation of GTL16 cells (IC₅₀=66.7 nM) .

HY-124267

Zgwatinib SOMG-833	c-Met/HGFR	Cancer
Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive *c-MET* inhibitor, with an IC₅₀ of 0.93 nM against c-MET, over 10,000-fold more potent compared with 19 tyrosine kinases (including c-MET family members and highly homologous kinases). Zgwatinib potently inhibits c-MET-driven cell proliferation. Zgwatinib as a potential candidate agent for c-MET-driven human cancers research .

HY-14723

AMG-458

c-Met/HGFR Cancer

AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with K_i values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively .

AMG-458	c-Met/HGFR	Cancer
AMG-458 is a potent, selective and orally bioavailable *c-Met* inhibitor, with K_i values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively .

HY-116000

Glumetinib 1 Publications Verification Gumarontinib; SCC244	c-Met/HGFR	Cancer
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .

HY-144394

Antitumor agent-45	Apoptosis c-Met/HGFR	Cancer
Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells .

HY-14721

Tepotinib 5 Publications Verification EMD-1214063	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) is a potent and highly selective *c-Met* inhibitor with an IC₅₀ of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Antitumor effects .

HY-50686

Tivantinib

5+ Cited Publications

ARQ 197; (3R,4R)-ARQ 198
c-Met/HGFR Apoptosis Cancer

Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a K_i of 355 nM.

Tivantinib 5+ Cited Publications ARQ 197; (3R,4R)-ARQ 198	c-Met/HGFR Apoptosis	Cancer
Tivantinib is a highly selective *c-Met* tyrosine kinase inhibitor with a K_i of 355 nM.

HY-13404

Capmatinib 5+ Cited Publications INC280; INCB28060	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404B

Capmatinib hydrochloride INC280 hydrochloride; INCB-28060 hydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404C

Capmatinib dihydrochloride hydrate 5+ Cited Publications INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404A

Capmatinib dihydrochloride INC280 dihydrochloride; INCB28060 dihydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-12017

PF-04217903 2 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-12017A

PF-04217903 mesylate 2 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 mesylate is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 mesylate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-12017B

PF-04217903 phenolsulfonate	c-Met/HGFR	Cancer
PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-124875

Arylsulfonamide 64B HIF inhibitor 64B	HIF/HIF Prolyl-Hydroxylase	Neurological Disease
Arylsulfonamide 64B (HIF inhibitor 64B) is an inhibitor of the hypoxia-induced factor (HIF)*. Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met* and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma mouse model .**

HY-15240

c-Kit-IN-1

c-Kit c-Met/HGFR Cancer

c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC₅₀s of <200 nM.
HY-50703

MK-2461

1 Publications Verification

c-Met/HGFR Cancer

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits *c-Met* receptor-mediated cancer cell proliferation, migration, and invasion .

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1045 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1045 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L101

Anti-Liver Cancer Compound Library

1798 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 1798 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P1415A

Norleual TFA 1 Publications Verification	c-Met/HGFR Angiotensin Receptor	Neurological Disease Metabolic Disease
Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .

HY-P1415

Norleual	c-Met/HGFR Angiotensin Receptor	Neurological Disease Metabolic Disease
Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .

Cat. No.	Product Name	Target	Research Area

HY-P99391

Telisotuzumab ABT-700	Inhibitory Antibodies	Cancer
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits *c-Met* receptor-mediated cancer cell proliferation, migration, and invasion .

HY-P99455

Bafisontamab

EMB-01
EGFR c-Met/HGFR Cancer

Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .

HY-P990306

ABBV-303	c-Met/HGFR ADC Antibody	Cancer
ABBV-303 is a multi-specific NK cell antibody targeting *c-Met* designed based on TriNKET technology for natural killer (NK) cell redirection therapy. The ABBV-303 antibody consists of three functional arms, a single-chain variable fragment (scFV) targeting c-Met, a Fab arm targeting NKG2D, and an Fc fragment targeting NK cell CD16a.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6797

Meleagrin	Infection Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Bacterial c-Met/HGFR Antibiotic
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead *c-Met* inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies .

Species:	Human (6)
Tag:	His (5) Avi (2) Fc (1)
Source:	HEK293 (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P78490

	HGFR Protein, Human (HEK293, His-Avi) Met; oncogene Met; HGF R; HGF/SF receptor; AUTS9; cMet; Met (c-Met); RCCP2; SF receptor	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, His-Avi) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of HGFR Protein, Human (HEK293, His-Avi) is 908 a.a., with molecular weight of 45-60 kDa & 80-100 kDa, respectively.

HY-P701263

	FITC-Labeled HGFR Protein, Human (HEK293, His) Met; AUTS9; HGFR; RCCP2; c-Met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. FITC-Labeled HGFR Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled HGFR protein, expressed by HEK293 , with His labeled tag. The total length of FITC-Labeled HGFR Protein, Human (HEK293, His) is 908 a.a., with molecular weight of 30-40 kDa & 90-100 kDa & 150 kDa, respectively.

HY-P72376

	HGFR Protein, Human (Biotinylated, HEK293, His-Avi) Hepatocyte growth factor receptor; Proto-oncogene c-Met; SF receptor; Tyrosine-protein kinase Met; Met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of HGFR Protein, Human (Biotinylated, HEK293, His-Avi) is 908 a.a., with molecular weight of 75-95 & 40-50 kDa, respectively.

HY-P70714

	HGFR Protein, Human (HEK293, His) Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met; Met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of HGFR Protein, Human (HEK293, His) is 908 a.a., with molecular weight of 130 & 80-95 & 40-50 kDa, respectively.

HY-P70715

	HGFR Protein, Human (HEK293, Fc) Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met; Met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, Fc) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of HGFR Protein, Human (HEK293, Fc) is 908 a.a., with molecular weight of 170 & 100-130 & 45-50 kDa, respectively.

HY-P72624

	HGFR Protein, Human (495a.a, HEK293, His) Hepatocyte growth factor receptor; HGF receptor; SF receptor; Met	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (495a.a, HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of HGFR Protein, Human (495a.a, HEK293, His) is 495 a.a., with molecular weight of 32 & 35-57 kDa, respectively.

Cat. No.	Product Name	Chemical Structure

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Cat. No.	Product Name	Application	Reactivity

HY-P80219

*Met (C-Met) Antibody*	WB, ICC/IF, IHC-P, FC	Human
Met (C-Met) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 156 kDa, targeting to Met (C-Met). It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human.

HY-P80803

*Phospho-c-Met* (Tyr1349) Antibody** Met; Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met	WB, IP	Human
Phospho-c-Met (Tyr1349) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 156 kDa, targeting to Phospho-c-Met (Tyr1349). It can be used for WB,IP assays with tag free, in the background of Human.

Cat. No.	Product Name		Classification

HY-149880

c-Met-IN-18		Alkynes
c-Met-IN-18 is ATP competitive type-III c-MET inhibitor of WT and D1228V mutant c-MET. c-Met-IN-18 has inhibitory for WT/D1228V with an IC₅₀ value of 0.013/0.20 ^e.c-Met-IN-18 can be used for the research of c-MET driven cancers . c-Met-IN-18 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153831

c-Met-IN-17		Alkynes
c-Met-IN-17 is a potent *c-Met* kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry